N-3 Fatty Acids in low dose don't protect our hearts

EPA-DHA and ALA not so good at heart protection in low doses

self park Chicago New data published in the New England Journal of Medicine (NEJM 2010;363:2015-2-26 Nov 18th) give results from awell-designed (multi-center, placebo-controlled and double-blind) trial. The Alpha Omega Trial group reports that in 4837 patients between 60 and 80 who had a heart attack (myocardial infarction) and who also got currently recommended blood pressure, abnormal clot preventing and cholesterol (lipid lowering) treatments did not show a significantly different results versus patients who got placebo over the 40 months of the study.

The people had an average of 18.8 grams of margarine a day. Interestingly, ALA (1.9 grams daily) or EPA-DHA (226 mg/150 mg) did not lower the risk of having a fatal or non-fatal heart or blood vessel event (cardiovascular event) or a cardiac intervention. What may be important is that Alpha-Linoleic Acid (ALA) alone (compared to placebo or EPA-DHA) WAS linked to a lowering of major heart and blood vessel events that DID approach being significant). The authors conclude that low-dose ALA or EPA-DHA didn't lower rates of cardiovascular events in the patients studied. I wonder what would have happened if the Alpha-Linoleic Acid (ALA) daily dose was increased. This looks like an area full of potential for research.


This website is not intended as medical advice, and you should consult your doctor before changing or adding any medicines or vitamins to those you may now be taking and about applying any strategies BEFORE you adopt any approach in this report. While diligent care has been taken to ensure the accuracy of the information provided during the preparation of this edition, no claim is made that all known actions, uses or side effects, strategies for cost containment, targets or cholesterol pathways are included in this report. The accuracy and currentness of information are ever subject to change relative to new guidelines, new information derived from drug research, development and general usage.